Skip to main
AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 50%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics is poised for growth with their successful drug Sunosi generating a 34% increase in revenue and upcoming plans for expansion into new indications. The company has a strong cash position and a promising pipeline, including a recently acquired drug for schizophrenia and Tourette syndrome. The author maintains a Buy rating with an increased 12-month price target, but it's important to note potential risks and limitations that could affect the company's future success.

Bears say

Axsome Therapeutics is currently experiencing strong revenue growth, with net product revenue of $153.2M in 1Q26 and a 59% year-over-year increase. However, the company's reliance on a single operating segment and reporting unit, as well as potential challenges with FDA approval for its key pipeline products, may limit its long-term revenue potential. Additionally, with its relatively low payer coverage across all channels, it may struggle to expand its customer base and achieve sustainable growth in the competitive CNS disorders market.

Axsome Therapeutics (AXSM) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 50% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 16 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $244, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $244, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.